Although approximately 31,000 Australian gay and bisexual men (GBM) are eligible for HIV pre-exposure prophylaxis (PrEP), only 18,500 people currently use it, indicating a need to investigate why GBM do not use it. This article uses data from a national, online, observational study. It adopts a mixed-methods analysis to responses to survey questions asking about reasons Australian GBM were not using PrEP in 2018, according to their level of HIV risk as delineated by the Australian PrEP prescribing guidelines at the time. Participants responded to check-box questions and had the option to respond to a qualitative free-text question. Results showed that just over one-fifth of men were at higher risk of HIV acquisition. Compared to lower-risk men, higher-risk men were more likely to indicate PrEP was too expensive and more likely to cite embarrassment asking for it. Reasons for not using PrEP included a lack of personal relevance, poor accessibility or knowledge, concerns about PrEP's inability to protect against STIs, potential side effects, and a preference for condoms. We conclude that health promotion more effectively targeting GBM who may benefit the most from PrEP may be valuable.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/08964289.2022.2033159 | DOI Listing |
Transgend Health
December 2024
Department of Epidemiology, Emory University, Atlanta, Georgia, USA.
Purpose: Using a community-engaged approach, we adapted a human immunodeficiency virus (HIV) prevention smartphone app, Transpire, to meet the HIV and sexually transmitted infection (STI) prevention needs of transgender men and other transmasculine people. We conducted a pilot study to assess the feasibility and acceptability of the app among participants in two cities in the southeastern United States.
Methods: Participants were recruited online and through community partners.
Transgend Health
December 2024
Fenway Health, The Fenway Institute, Boston, Massachusetts, USA.
Purpose: Transgender and nonbinary adults (TNB) are disproportionately burdened by sexually transmitted infections (STI) and the human immunodeficiency virus (HIV). This study investigated whether gender-affirming hormone therapy was associated with TNB adults' odds of screening for STI and HIV.
Methods: Longitudinal data came from the electronic medical records of TNB primary care patients receiving care at two community health centers located in Boston, Massachusetts, and New York City, New York, between January 2013 and December 2019.
Front Reprod Health
December 2024
Bureau of Global Health Security and Diplomacy, President's Emergency Plan for AIDS Relief (PEPFAR), Office of Program Impact, Monitoring, and Epidemiology (PRIME), U.S. Department of State, Washington, DC, United States.
Background: In 2023, an estimated 1.3 million people newly acquired HIV. In the same year, 3.
View Article and Find Full Text PDFAIDS Care
December 2024
School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Objective measures of oral PrEP adherence - especially point-of-care (POC) measures that enable real-time assessment, intervention, and feedback - have the potential to improve adherence. Our team previously developed and validated a novel urine-based POC metric of PrEP adherence. In this study, we sought to determine whether this assay is acceptable and feasible among women taking PrEP and PrEP providers in Kenya.
View Article and Find Full Text PDFMCN Am J Matern Child Nurs
October 2024
Jillian Pintye is an Associate Professor at the University of Washington School of Nursing, Seattle, WA. Dr. Pintye can be reached at
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!